secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001437749-23-031996
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics Q3 revenue up 27% to $2.19M; net loss widens to $10.4M
-------------------------------------------------------------------------------

- Revenue $2.19M (+27% YoY); sales revenue $1.9M (+11%); gross profit $738K vs $414K.
- Net loss $10.4M ($0.04/sh) vs $4.1M ($0.03/sh); R&D expenses surged 708% to $5.7M.
- Cash $18.0M at Sept 30, 2023 (from $43.9M at Dec 31, 2022); runway into late Q2 2024.
- Dosed first patient in Phase 1/2a trial of [212Pb]VMT-α-NET for neuroendocrine tumors.
- Completed recruitment for first cohort of Phase 1/2a VMT01 trial for melanoma; no serious AEs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000143774923031996/0001437749-23-031996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000143774923031996/isr20231113_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-031996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer